Brief: Standard Biotools Expects To Reach Positive Free Cash Flow by Q4, 2024

Standard BioTools

09/01/2023 14:07

Jan 9 (Reuters) - Standard BioTools Inc  LAB.O :
    * STANDARD BIOTOOLS PROVIDES PRELIMINARY Q4 2022 REVENUE AND
BUSINESS UPDATE
    * COMPANY EXPECTS TO REACH POSITIVE FREE CASH FLOW IN Q4 OF
2024
    * FOR Q4, CORE PRODUCT AND SERVICE REVENUES ARE EXPECTED TO
BE IN
RANGE OF $26 MILLION-$27 MILLION
    * EXPECTS LOWER NON-GAAP OPERATING EXPENSES BY MORE THAN $30
MILLION IN 2023 COMPARED TO 2022
    * FOR FULL YEAR, CORE PRODUCT AND SERVICE REVENUES ARE
EXPECTED TO
BE IN RANGE OF APPROXIMATELY $94 MILLION-$95 MILLION

Source text for Eikon:  ID:nGNX1hFbzJ 
Further company coverage:  LAB.O 
 ((Reuters.Briefs@thomsonreuters.com))